Company Profile
Minerva Neuroscience Stock Price, News & Analysis
- Ticker:
- NERV
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.21 USD (+4.08%)
Close
Last updated: July 27, 2026
221M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, NERV closed up 4.08% at $4.21. No new same-company headline was identified in the current news window.
Company overview
Business overview
Minerva Neurosciences is a neuroscience company focused on psychiatric and CNS disorders. Its pipeline has centered on difficult brain-health programs with high unmet need.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Minerva sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical validation, financing, and the ability to create a credible CNS story.
Position Within the Biotechnology Landscape
Minerva is a high-risk CNS name whose valuation depends on early data and strategic clarity.
Future catalysts
Minerva Neurosciences’ catalysts are roluperidone and the negative-symptom schizophrenia program, where the next update could materially change the market’s view. The company still needs a clean clinical step.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BCLI · Source: Brainstorm Cell Therapeutics Inc.
- 02
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
DNLI · Source: Denali Therapeutics
- 03
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
TNXP · Source: Tonix Pharmaceuticals
- 04
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
IKT · Source: Inhibikase Therapeutics
- 05
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
KTTA · Source: Pasithea Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Minerva Neuroscience (NERV)?
Minerva Neuroscience (NERV) most recently closed at 4.21 USD, a +4.08% move versus the previous session.
What is the market cap of Minerva Neuroscience (NERV)?
Minerva Neuroscience currently has a market capitalization of 221M USD on BioPharmSignal.
What does Minerva Neuroscience do?
Minerva Neurosciences is a neuroscience company focused on psychiatric and CNS disorders. Its pipeline has centered on difficult brain-health programs with high unmet need.
On which exchange is NERV stock listed?
Minerva Neuroscience (NERV) is associated with NASDAQ, United States, Biopharma.
What is Minerva?
Minerva Neurosciences’ catalysts are roluperidone and the negative-symptom schizophrenia program, where the next update could materially change the market’s view.
Which conditions is Minerva Neuroscience targeting with Minerva?
Minerva Neuroscience is associated with neuroscience based on its company overview and current catalyst commentary.
How does Minerva Neuroscience describe recent progress with Minerva?
Minerva Neurosciences’ catalysts are roluperidone and the negative-symptom schizophrenia program, where the next update could materially change the market’s view.
What is Neurosciences?
Minerva Neurosciences is a neuroscience company focused on psychiatric and CNS disorders.